ATE269848T1 - Calciumkanalblocker als antikrebsmittel - Google Patents

Calciumkanalblocker als antikrebsmittel

Info

Publication number
ATE269848T1
ATE269848T1 AT00921867T AT00921867T ATE269848T1 AT E269848 T1 ATE269848 T1 AT E269848T1 AT 00921867 T AT00921867 T AT 00921867T AT 00921867 T AT00921867 T AT 00921867T AT E269848 T1 ATE269848 T1 AT E269848T1
Authority
AT
Austria
Prior art keywords
anticancer
calcium channel
channel blockers
compounds
directed
Prior art date
Application number
AT00921867T
Other languages
English (en)
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Application granted granted Critical
Publication of ATE269848T1 publication Critical patent/ATE269848T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00921867T 1999-04-07 2000-04-07 Calciumkanalblocker als antikrebsmittel ATE269848T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12814399P 1999-04-07 1999-04-07
PCT/US2000/009310 WO2000059882A1 (en) 1999-04-07 2000-04-07 Anticancer calcium channel blockers

Publications (1)

Publication Number Publication Date
ATE269848T1 true ATE269848T1 (de) 2004-07-15

Family

ID=22433855

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00921867T ATE269848T1 (de) 1999-04-07 2000-04-07 Calciumkanalblocker als antikrebsmittel

Country Status (6)

Country Link
EP (1) EP1165508B1 (de)
JP (1) JP4932994B2 (de)
AT (1) ATE269848T1 (de)
CA (1) CA2369588C (de)
DE (1) DE60011755T2 (de)
WO (1) WO2000059882A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1633343A1 (de) * 2003-05-30 2006-03-15 Neuromed Technologies, Inc. 3-aminomethylpyrrolidine als calciumkanalantagonisten vom n-typ
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
US7504431B2 (en) 2004-04-16 2009-03-17 Bristol-Myers Squibb Company Sulfonyl amide inhibitors of calcium channel function
AU2005277154B2 (en) * 2004-08-20 2011-11-24 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
CN101686952A (zh) 2007-03-12 2010-03-31 Vm生物医药公司 新型钙离子通道调节剂
CN101888780B (zh) 2007-10-05 2014-08-13 生华生物科技股份有限公司 喹诺酮类似物及其相关方法
ES2842289T3 (es) 2008-02-29 2021-07-13 Vm Therapeutics Llc Compuestos para tratar el síndrome del dolor y otros trastornos
CA2718949C (en) 2008-03-19 2021-05-04 Soricimed Biopharma Inc. Peptide compositions for cancer treatment
CN102239146A (zh) 2008-10-02 2011-11-09 雅培制药有限公司 作为钙通道阻断剂的新化合物
AR074226A1 (es) * 2008-11-26 2010-12-29 Abbott Lab Octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio, composiciones farmaceuticas que las comprenden y el uso de las mismas para el tratamiento del dolor.
TW201028421A (en) 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
EP2445932B1 (de) 2009-06-26 2018-02-28 Soricimed Biopharma Inc. Soriciden-abgeleitete peptide und verfahren zum nachweisen von trpv-6-krebsarten und medikamentenverabreichung
CA2787673A1 (en) 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
WO2011115813A1 (en) 2010-03-18 2011-09-22 Abbott Laboratories Lactam acetamides as calcium channel blockers
US8796470B2 (en) 2010-05-25 2014-08-05 Abbvie Inc. Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators
WO2011149995A1 (en) 2010-05-25 2011-12-01 Abbott Laboratories Novel substituted octahydrocyclopenta [c]pyrrol-4-amines as calcium channel blockers
WO2013049164A1 (en) 2011-09-29 2013-04-04 Abbvie Inc. SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS
WO2013049174A1 (en) 2011-09-29 2013-04-04 Abbvie Inc. Substituted octahydropyrrolo[1,2-a]pyrazine sulfonamides as calcium channel blockers
KR20150093237A (ko) 2012-12-12 2015-08-17 애브비 인코포레이티드 통증 치료시 칼슘 채널 차단제로서 유용한 디아제핀 유도체
CA3005730A1 (en) 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
TWI884912B (zh) 2018-02-15 2025-06-01 生華生物科技股份有限公司 喹啉酮類似物及其鹽、組合物及其使用方法
CN115215800B (zh) * 2021-04-21 2023-07-18 赣江中药创新中心 一种二苯并环基-环胺基醚衍生物或盐及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2454092A (en) * 1947-06-02 1948-11-16 Parke Davis & Co Benzhydryl amino ethers
US2708194A (en) * 1952-12-10 1955-05-10 Univ Michigan 2-(1-methyl) polymethyleniminylmethyl benzhydryl ethers and preparation thereof
GB833807A (en) * 1957-07-10 1960-04-27 Beecham Res Lab Benzhydryl ethers
US3732247A (en) * 1970-08-14 1973-05-08 Robins Co Inc A H 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms
GB1307255A (en) * 1970-09-12 1973-02-14 Pfizer Ltd Substituted basic benzhydryl ethers
FR2601366B1 (fr) * 1986-07-10 1988-11-25 Andre Buzas Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant.
FR2636946B1 (fr) * 1988-09-23 1990-11-02 Lipha ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant
GB9000301D0 (en) * 1990-01-06 1990-03-07 Pfizer Ltd Piperidine & pyrrolidine derivatives
MX9100513A (es) * 1990-08-06 1992-04-01 Smith Kline French Lab Compuestos
GB9020051D0 (en) * 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
ATE256110T1 (de) * 1995-09-15 2003-12-15 Neurosearch As Piperindinverbindungen als calcium-kanal-blocker
CA2204082A1 (en) * 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
JPH1135483A (ja) * 1997-05-20 1999-02-09 Nippon Kayaku Co Ltd 頻尿又は尿失禁の治療剤又は予防剤

Also Published As

Publication number Publication date
EP1165508B1 (de) 2004-06-23
EP1165508A1 (de) 2002-01-02
DE60011755T2 (de) 2005-06-30
JP2002541142A (ja) 2002-12-03
CA2369588C (en) 2011-02-08
JP4932994B2 (ja) 2012-05-16
WO2000059882A1 (en) 2000-10-12
WO2000059882A9 (en) 2001-11-29
CA2369588A1 (en) 2000-10-12
DE60011755D1 (de) 2004-07-29

Similar Documents

Publication Publication Date Title
DE60011755D1 (de) Calciumkanalblocker als antikrebsmittel
NZ506329A (en) Inhibitors of phospholipase enzymes
AU9263101A (en) Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
PL360373A1 (en) Non-imidazole aryloxypiperidines as h3 receptor ligands
DE60007329D1 (de) N-heterozyklische derivate als nos inhibitoren
WO2001071022A3 (en) Lpa receptor agonists and antagonists and methods of use
WO2004044160A3 (en) Muc1 interference rna compositions and methods derived therefrom
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
PT1313721E (pt) Ariloxialquilaminas nao imidazoles como ligandos de receptor h3
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
AU4820101A (en) Novel compounds for modulating cell proliferation
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE60001850D1 (de) Chalcon coumarine
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
DE602004012146D1 (en) Pyrazolopyrimidine
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
MXPA05006507A (es) Inhibidores de ccxckr2 expresado en tumor humano.
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
EE200300156A (et) Kasvajarakkude kasvufaktoritest sõltuvuse pärssimine
ATE259886T1 (de) Ledergerben
DE60100539D1 (en) Tosylprolin-derivate als thymidylat-synthase inhibitoren
DE60011677D1 (en) Tryptase-inhibitoren
SI1244614T1 (en) Tryptase inhibitors
DE602004004093D1 (de) Alkylierte iminodibenzyle als antioxidationsmittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties